CLOs may need treatment as Valeant's stock plummets
CLOs could be in for testing times after damaging allegations against widely-held leveraged loan issuer Valeant Pharmaceuticals were published yesterday
Subscriber-only article
This article is available only to Creditflux subscribers and free trial users within 30 days of publication.
Already a subscriber? Not logged in? Click here to login.
If you have not already done so,
you may request a FREE TRIAL by clicking here
This trial will give you:
- 4-weeks' free online access to our
most recent subscriber-only articles - Daily breaking news alert sent by email
- A print copy of Creditflux
If you currently have a free trial, you will see this message when you try to view articles older than 30 days.
Related Stories
- Strong run helps CLOs shrug off Altice downgrade 4 days ago
- US loan volume nears record levels 5 days ago
- Credit hedge funds 5 days ago
- Relative to Airbus, Boeing was long accountants but short engineers 5 days ago
- IACPM survey finds credit PMs still gloomy, but less so than last quarter 11 days ago
CLOs
- European reset highlights weakness in mezz despite robust senior demand 7 hours ago
- Elmwood prints eighth deal this year 7 hours ago
- Partnership with Jefferies bears fruit as manager returns to CLO primary 1 day ago
- US resets continue as Redding Ridge joins in 1 day ago
- Sycamore resets and upsizes 2023 vintage CLO 1 day ago